DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab-merket, grunnlagt 2010 (forente stater), fra 496 tilknyttede merkevarer og 17478 konkurrerende merkevarer. DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab er et merke fra BRISTOL-MYERS SQUIBB COMPANY, børsnotert i New York. DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab kommer under Legemiddelprodusenter-bransjen.

DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab er et varemerke som tilhører BRISTOL-MYERS SQUIBB COMPANY (BMY) Nyheter

BRISTOL-MYERS SQUIBB COMPANY (DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab) aksjekurs

Aksjekurs
Populariteten til DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab (BRISTOL-MYERS SQUIBB COMPANY)

Popularitet
Bærekraft BRISTOL-MYERS SQUIBB COMPANY

Bærekraftig utvikling
Andre merkevarer BRISTOL-MYERS SQUIBB COMPANY

Andre merker
Konkurrerende merker av DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab

Konkurrerende merker
Nyheter

Nyheter

Alle nyhetene
BRISTOL-MYERS SQUIBB COMPANY (DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)

Børs: Mer informasjon om BRISTOL-MYERS SQUIBB COMPANY (DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)

DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab er et varemerke som tilhører BRISTOL-MYERS SQUIBB COMPANY (BMY) Nyheter

Alle nyhetene BRISTOL-MYERS SQUIBB COMPANY (DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)

Alle nyhetene
BRISTOL-MYERS SQUIBB COMPANY (DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)